One-year effects of omega-3 treatment on fatty acids, oxylipins, and related bioactive lipids and their associations with clinical lipid and inflammatory biomarkers: Findings from a substudy of the vitamin d and omega-3 trial (vital)

Olga V. Demler, Yanyan Liu, Heike Luttmann-Gibson, Jeramie D. Watrous, Kim A. Lagerborg, Hesam Dashti, Franco Giulianini, Mallory Heath, Carlos A. Camargo, William S. Harris, Jay G. Wohlgemuth, Allen M. Andres, Saumya Tivari, Tao Long, Mahan Najhawan, Khoi Dao, James G. Prentice, Julia A. Larsen, Olivia I. Okereke, Karen H. CostenbaderJulie E. Buring, Joann E. Manson, Susan Cheng, Mohit Jain, Samia Mora

Research output: Contribution to journalArticlepeer-review

Abstract

Omega-3 (n-3) treatment may lower cardiovascular risk, yet its effects on the circulating lipidome and relation to cardiovascular risk biomarkers are unclear. We hypothesized that n-3 treatment is associated with favorable changes in downstream fatty acids (FAs), oxylipins, bioactive lipids, clinical lipid and inflammatory biomarkers. We examined these VITAL200, a nested substudy of 200 subjects balanced on demographics and treatment and randomly selected from the Vitamin D and Omega-3 Trial (VITAL). VITAL is a randomized double-blind trial of 840 mg/d eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) vs. placebo among 25,871 individuals. Small polar bioactive lipid features, oxylipins and FAs from plasma and red blood cells were measured using three independent assaying techniques at baseline and one year. The Women's Health Study (WHS) was used for replication with dietary n-3 intake. Randomized n-3 treatment led to changes in 143 FAs, oxylipins and bioactive lipids (False Discovery Rate (FDR) < 0.05 in VITAL200, validated (p-values < 0.05)) in WHS with increases in 95 including EPA, DHA, n-3 docosapentaenoic acid (DPA-n3), and decreases in 48 including DPA-n6, dihomo gamma linolenic (DGLA), adrenic and arachidonic acids. N-3 related changes in the bioactive lipidome were heterogeneously associated with changes in clinical lipid and inflammatory biomarkers. N-3 treatment significantly modulates the bioactive lipidome, which may contribute to its clinical benefits.

Original languageEnglish (US)
Article number431
Pages (from-to)1-20
Number of pages20
JournalMetabolites
Volume10
Issue number11
DOIs
StatePublished - Nov 2020

Keywords

  • Bioactive lipids
  • Clinical trial
  • Free fatty acids
  • Inflammatory biomarkers
  • Lipids
  • Metabolomics
  • Omega-3
  • Oxylipins

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology

Fingerprint Dive into the research topics of 'One-year effects of omega-3 treatment on fatty acids, oxylipins, and related bioactive lipids and their associations with clinical lipid and inflammatory biomarkers: Findings from a substudy of the vitamin d and omega-3 trial (vital)'. Together they form a unique fingerprint.

Cite this